Prognosis and Risk Factors for Acute Kidney Injury

NCT06898944 | Recruiting

• 1 other identifier: H-2208-015-1347
• Study Type: observational
• Target: 320,000
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of our study is to analyze the accurate diagnosis and prognosis of acute kidney injury (AKI) based on its severity and to define long-term clinical and socioeconomic outcomes. Investigators defined the AKI group among adults aged 20 years or older who visited enrolled center and underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less and a control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population. Investigators then collected and analyzed various clinical, laboratory, and hospitalization records including demographic data, anthropometric data, laboratory data, and medical history.

Conditions

Acute Kidney Injury

Outcome Measures

Primary Outcomes (1)

• Change from Baseline in Serum Creatinine

  From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date

Secondary Outcomes (4)

• Change from Baseline in Urine Protein/Creatinine Ratio

  From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date

• Incidence of Receiving Renal Replacement Therapy

  From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date

• Change from Baseline in Serum Hemogloblin Level

  From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date

• Change from Baseline in Serum Albumin Level

  From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date

Study Arms (2)

AKI group

* Aged 20 years or older who visited hospital * Underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less * AKI was defined based on the KDIGO criteria (an increase in serum creatinine by ≥0.3 mg/dL or ≥1.5 times the baseline).

Control group

Control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population.

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults (≥20 years old) who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021

You may qualify if:

• Adults over 20 years old who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021
• The AKI group is defined as individuals meeting the AKI diagnostic criteria of the KDIGO Guideline (an increase in serum creatinine of ≥0.3 mg/dL or ≥1.5 times the baseline level) is enrolled.
• The Control Group is defined as individuals from the study population who do not meet the AKI criteria and are matched 1:1 based on age, sex, year of visit, and baseline renal function.

You may not qualify if:

• Individuals under 20 years old
• Individuals who did not undergo serum creatinine tests meeting the criteria
• Individuals with pre-existing end-stage kidney disease (ESKD) who have undergone dialysis or kidney transplantation

Sponsors & Collaborators

• Seoul National University Hospital: lead
• Seoul National University Bundang Hospital: collaborator
• SMG-SNU Boramae Medical Center: collaborator
• Keimyung University Dongsan Medical Center: collaborator

Study Sites (1)

Seoul National University Hospital

Seoul, 03080, South Korea

RECRUITING

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Dong Ki Kim, M.D. Ph.D.

  Department of Internal Medicine, Seoul National University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sehoon Park, M.D. Ph.D.

CONTACT

+82-02-2072-4070; mailofsehoon@gmail.com

Jin Kyung Kwon, M.D.

CONTACT

+82-02-2072-4070; jkk1456@naver.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 20, 2025
• First Posted: March 27, 2025
• Study Start: August 22, 2022
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: April 2, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will share

Locations

KR (1)